Diagnostic antibodies against IL-6 with high sensitivity and wide dynamic range!
Icosagen has developed high sensitivity monoclonal antibodies against IL-6 with wide dynamic range. We have 6 different antibody clones available, which experimentally show no cross-reactivity with IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-8, IFNγ, TNFα cytokines.In addition to antibodies, recombinant human IL-6 antigen is in stock.
Read more ›
Icosagen stands with Ukraine
Democracy, peace and freedom are the most fundamental values of society. Unfortunately, the unjustifiable war in Ukraine is a painful reminder that we cannot take it for granted. Icosagen stands with Ukraine.
Read more ›
High quality Omicron antibodies and proteins now available!
Omicron variant accounts for almost all new
COVID-19 cases around the world. In Icosagen we have tested our developed
antibodies against different SARS-CoV-2 Spike variants, and now also with the
dominant Omicron variant. We offer antibodies with high affinity to
Omicron variant and also antibodies binding to other variants, without binding
to Omicron.
Read more ›
Icosagen Strengthens BD Team with Oliver Schub for Next Level Growth Stage: Stable CHO Cell Line Development and Therapeutic Protein Production
Icosagen Group has
been steadily and strongly growing over the past years to more than 120
employees. We have built a world-wide reputation for therapeutic antibody
discovery and recombinant antibody/protein production for our IVD, biotech, and
pharma partners, based on our patented HybriFree and QMCF Technology Platforms.
Recently, we successfully ventured even into the medical products world, with
our Bioblock® anti-Covid19 nasal spray.
Read more ›
SARS-CoV-2 Trimeric Spike, S1 and RBD Omicron proteins are now available!
We are keeping up with the virus by producing SARS-CoV-2 Omicron variant (B.1.1.529) as Trimeric Spike, S1 and RBD. All of these are produced recombinantly in CHO cells and shown to be functional. Furthermore, we will have Omicron version of Nucleocapsid protein available with P13L, del31-33, R203K and G204R mutations in few weeks.
Read more ›
Seasons’s Greetings from the Icosagen Team
All of us at Icosagen wish you the best in this holiday
season and upcoming year!
Read more ›
Icosagen's COVID-19 antibody ELISA test is available for diagnostics with an IVD CE mark
Press release: Icosagen Cell Factory was awarded EUR 1.2 million
HybriFree recombinant antibody development article is published
Icosagen AS has incorporated a US subsidiary – Icosagen Technologies, Inc.
The Icosagen Cell Factory OÜ team is looking for a MARKETING SPECIALIST
QMCF Technology to be presented at the CHI's 14th Annual PepTalk conference in San Diego, California
Icosagen Cell Factory was titled the Best Entrepreneur of 2013
Icosagen Cell Factory presentation at Cell Line Development Conference